Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay – STAT
|
Combination immunotherapy may have failed in the Incyte/Merck trial, but it's here to stay
STAT he failure of Incyte's Phase 3 clinical trial of epacadostat combined with Keytruda, Merck's breakthrough checkpoint inhibitor, for people newly diagnosed with melanoma was a big disappointment to the companies, the pharmaceutical industry, and … |
